Kennedy’s Vaccine Agenda Stalled by Court, Structure’s Obesity Pill Advances, Novo Nordisk Faces FDA Warning

on

A Massachusetts federal judge ruled that Health Secretary Robert F. Kennedy Jr.’s overhaul of vaccine policy, including firing the CDC’s ACIP members and changes to the childhood vaccine schedule, likely violated the Administrative Procedure Act, stalling the agenda124.

Structure Therapeutics’ investigational GLP-1 oral weight loss pill showed 16.3% weight loss after 44 weeks in Phase 2, described as having a 'competitive profile' against Eli Lilly’s orforglipron and Novo’s oral Wegovy1.

Novo Nordisk received an FDA warning letter for failing to investigate adverse events, including three deaths, potentially linked to Ozempic1.

Eli Lilly warned of safety risks with compounded versions of tirzepatide (Zepbound/Mounjaro)1.

Rhythm Pharmaceuticals’ Imcivree failed in a Phase 3 basket trial for genetically driven obesities1.

The ruling halted ACIP appointments and votes, with nearly 30 states not following the new schedule; Trump administration response unclear amid political risks23.

Sources:

1. https://www.biospace.com/fda/kennedys-vaccine-agenda-stalled-structures-competitive-obesity-pill-novos-warning-letter

2. https://www.statnews.com/2026/03/16/kennedy-childhood-vaccine-changes-blocked-judge/

3. https://www.statnews.com/2026/03/20/kennedy-vaccine-agenda-acip-disbanded-or-aap-lawsuit-appeal-trump-role/

4. https://www.cbsnews.com/news/judge-blocks-parts-of-rfk-jrs-vaccine-agenda-including-new-childhood-vaccine-schedule/